# Schedules of Controlled Substances: Placement of 3-MeO-PCP in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/3-meo-pcp-schedule-i-dea-controlled-substance/ > **Published:** 2026-06-18T11:59:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T16:59:30-04:00 > **Clinical Summary:** Learn about 3-MeO-PCP Schedule I placement by the DEA, highlighting its high abuse potential and regulatory impact on controlled substances. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register cannabis_policyfederal_lawDEA_schedulingcontrolled_substances3-MethoxyphencyclidineSchedule_Istate_regulation Clinical Summary This regulatory action by the DEA places 3-methoxyphencyclidine (3-MeO-PCP), a synthetic drug structurally related to phencyclidine, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act, classifying it as having high abuse potential with no accepted medical use. The scheduling decision addresses the emerging [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) threat posed by designer drugs that evade existing controlled substance laws through minor chemical modifications while retaining psychoactive and dangerous properties similar to their parent compounds. This regulatory response reflects ongoing challenges in managing novel psychoactive substances that appear on the [illicit market](https://cedclinic.com/illicit-cannabis-market-risks-columbia-county-seizure/) faster than scheduling mechanisms can address them through traditional legal processes. Clinicians should be aware that patients presenting with acute intoxication, behavioral disturbances, or neuropsychiatric symptoms may have consumed emerging synthetic drugs like 3-MeO-PCP, which produce severe adverse effects including agitation, paranoia, seizures, and cardiovascular complications that mimic but may not respond to standard phencyclidine treatment protocols. Importantly, the Schedule I placement does not affect legitimate [cannabis prescribing](https://cedclinic.com/addressing-cannabis-education-gap-clinical-care/) or cannabinoid therapies, but highlights the broader regulatory landscape in which novel synthetic drugs compete with and may be substituted for [controlled substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/). Clinicians should maintain vigilance for unfamiliar psychoactive substances in their patients presenting with acute toxidromes and advocate for toxicology screening protocols that can detect emerging drugs beyond traditional panels. Clinical Perspective 💊 The DEA’s scheduling of 3-methoxyphencyclidine (3-MeO-PCP) as a Schedule I controlled substance addresses an emerging synthetic drug that has caused documented cases of severe psychiatric adverse effects, violent behavior, and medical complications in emergency departments. While this regulatory action reflects [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) concern about designer drugs that circumvent existing legislation, clinicians should recognize that scheduling decisions are made on a timeline that often lags behind real-world harms, meaning novel psychoactive substances may circulate before formal control occurs. The challenge for practitioners is that toxicology screens typically do not detect these designer compounds, so diagnosis relies on patient history, clinical presentation of dissociation and behavioral dyscontrol, and maintaining high suspicion when encountering unexplained psychosis or agitation. Understanding the regulatory landscape and timeline of synthetic [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/) informs clinicians to anticipate emerging substances in their communities and consider dissociative intoxication 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/ask-dr-caplan/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+3-Methoxyphencyclidine+%281-%281-%283-Methoxyphenyl%29cyclo...+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+3-Methoxyphencyclidine+%281-%281-%283-Methoxyphenyl%29cyclo...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) Related Articles - [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) - Schedules of [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/): Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I - [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/dea-synthetic-cannabinoids-schedule-i-placement-update/) 📰 Source: [https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoid-regulation-challenges-schedule-i-placement/) Explore the DEA’s scheduling of CUMYL-PEGACLONE in Schedule I and its implications for controlled substance regulation. [Read More](https://cedclinic.com/synthetic-cannabinoid-regulation-challenges-schedule-i-placement/) [Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) Detailed review of the DEA’s Schedule I placement of several synthetic cannabinoids and their regulatory impact. [Learn More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-placement/) [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-synthetic-cannabinoid-risks-schedule-i/) Understand the DEA’s decision to place MDMB-4en-PINACA in Schedule I and its significance in controlled substance law. [Discover More](https://cedclinic.com/mdmb-4en-pinaca-synthetic-cannabinoid-risks-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).